1. Home
  2. ADUS vs AKRO Comparison

ADUS vs AKRO Comparison

Compare ADUS & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Addus HomeCare Corporation

ADUS

Addus HomeCare Corporation

HOLD

Current Price

$111.97

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Logo Akero Therapeutics Inc.

AKRO

Akero Therapeutics Inc.

HOLD

Current Price

$54.65

Market Cap

4.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADUS
AKRO
Founded
1979
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
4.5B
IPO Year
2009
2019

Fundamental Metrics

Financial Performance
Metric
ADUS
AKRO
Price
$111.97
$54.65
Analyst Decision
Buy
Buy
Analyst Count
11
11
Target Price
$138.73
$73.56
AVG Volume (30 Days)
174.5K
2.4M
Earning Date
11-03-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
6.76
N/A
EPS
4.66
N/A
Revenue
$1,346,596,000.00
N/A
Revenue This Year
$25.50
N/A
Revenue Next Year
$7.11
N/A
P/E Ratio
$24.21
N/A
Revenue Growth
18.77
N/A
52 Week Low
$88.96
$21.34
52 Week High
$136.72
$58.40

Technical Indicators

Market Signals
Indicator
ADUS
AKRO
Relative Strength Index (RSI) 46.29 68.63
Support Level $110.07 $54.30
Resistance Level $116.00 $54.70
Average True Range (ATR) 2.92 0.17
MACD -0.27 -0.10
Stochastic Oscillator 26.27 71.07

Price Performance

Historical Comparison
ADUS
AKRO

About ADUS Addus HomeCare Corporation

Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, mainly to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are medical in nature to those individuals who may require assistance during an illness or after surgery.

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Share on Social Networks: